Institutional shares held 56.8 Million
51.2K calls
46K puts
Total value of holdings $1.14B
$1.03M calls
$920K puts
Market Cap $1.07B
53,458,100 Shares Out.
Institutional ownership 106.31%
# of Institutions 231


Latest Institutional Activity in CDNA

Top Purchases

Q2 2025
Mcf Advisors LLC Shares Held: 1.34K ($26.7K)
Q2 2025
Versant Capital Management, Inc Shares Held: 95 ($1.9K)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 209 ($4.18K)
Q2 2025
Uma Financial Services, Inc. Shares Held: 54 ($1.08K)
Q1 2025
Ophir Asset Management Pty LTD Shares Held: 1.62M ($32.4M)

Top Sells

Q2 2025
Exchange Traded Concepts, LLC Shares Held: 32.9K ($658K)
Q2 2025
Gamma Investing LLC Shares Held: 2.29K ($45.8K)
Q1 2025
Millennium Management LLC Shares Held: 103K ($2.05M)
Q1 2025
Bellevue Group Ag Shares Held: 889K ($17.8M)
Q1 2025
D. E. Shaw & Co., Inc. Shares Held: 783K ($15.7M)

About CDNA

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.


Insider Transactions at CDNA

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
858K Shares
From 18 Insiders
Grant, award, or other acquisition 680K shares
Exercise of conversion of derivative security 179K shares
Sell / Disposition
443K Shares
From 12 Insiders
Open market or private sale 311K shares
Payment of exercise price or tax liability 132K shares

Track Institutional and Insider Activities on CDNA

Follow CareDx, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CDNA shares.

Notify only if

Insider Trading

Get notified when an Care Dx, Inc. insider buys or sells CDNA shares.

Notify only if

News

Receive news related to CareDx, Inc.

Track Activities on CDNA